Immuno-Oncology Product Solutions
Accelerate Cancer Immunotherapeutic Discovery and Development with Cell-Based, Clinically Relevant Assays
Immuno-Oncology (IO) is a class of treatment modality designed to augment the body’s natural immune defense against cancer. The IO space is currently dominated by therapeutics development programs targeting immune checkpoint modulators and cytokines as these molecules hold significant promise in cancer therapy. Another key modality is the modulation of Fc-mediated effector mechanisms of therapeutic antibodies, including ADCC, ADCP, CAR-T, CAR-NK, CDC, and other cytotoxicity-focused applications.
Eurofins DiscoverX® offers the most comprehensive products portfolio of cell lines, cell pools, eXpress™ assay and bioassay kits, and retroparticles to enable fast, effective, and clinically relevant understanding of IO targets, their pathways, and mechanisms to empower quicker development of IO therapeutics. Continuous culture cell lines allow for full-scale interrogation, screening, and profiling of IO therapeutic MOAs (mechanism of actions), while the ready-to-use qualified bioassays are developed to meet the industry requirements and regulatory expectations. Eurofins DiscoverX offers fast and seamless implementation for IO therapeutic MOA confirmation, stability studies, and potency testing in QC lot release programs as a thaw-and-assay platform.
Learn how you can rapidly screen and develop small molecules, biologics (peptides, antibodies, or bispecific antibodies), or cellular therapies for your IO drug discovery and development program.
Product Highlights
- MOA-Reflective Assays – Designed for regulatory acceptance, these assays are intended to interrogate specific target biology for fast implementation through discovery, validation, characterization, and development stages of an intended therapeutic
- Broad Coverage of Checkpoint Modulators – Industry’s most comprehensive menu of stable cell lines and ready-to-use bioassays for targets including PD-1, SIRPα, CTLA4, OX40, ICOS, and many others
- Comprehensive Cytokine Receptor Assays – Functional assays for >85% of human interleukins receptors as well as cytokine-like interleukins, GM-CSF, interferons, chemokines, TNFα, TGF-β, and Ig superfamily receptor types
- Specific Cytotoxicity Assays – Specifically measure direct target cell death in co-cultures using relevant immune effector cells with KILR® cytotoxicity assays for ADCC, ADCP, CAR-T, T cell redirection, and adoptive T cell therapy
Fast-track your IO drug discovery and development with physiologically relevant cell-based assays. Eurofins DiscoverX offers the most comprehensive portfolio of cell-based assays to enable fast, effective, and clinically relevant understanding of IO to interrogate targets, pathways, and mechanisms to empower quicker development of IO therapeutics.
Products
- KILR® Cytotoxicity Assays – Non-radioactive, dye-free cytotoxicity assays to specifically measure targeted cell death in a co-culture with immune effector cells. Assays are designed to detect cancer cell death for applications like ADCC, CDC, ADCP, T cell redirection and CAR-T
- Checkpoint Receptor Assays – MOA-reflective functional assays enabling characterization, screening, lead optimization, and potency assay development of small molecule and biologic drugs for co-stimulatory and inhibitory checkpoint receptors. Assays include signaling; receptor dimerization, internalization, and clustering; and bispecific antibody development modalities
- Cytokine Receptor Assays – Cell-based assays for characterization, functional screening, QC lot release testing, and neutralizing antibody studies of drugs targeting cytokine/interleukin receptors. Assays include receptor dimerization, SH2 recruitment, IkB degradation, β-arrestin recruitment, and STAT3 transcriptional reporter mechanisms
- Signaling Reporter Assays – Orthogonal, functional cell-based assays with a downstream read-out used for screening and quantifying activation and inhibition of various signaling pathways
Whether you are developing small molecule or biologic therapeutics, Eurofins DiscoverX provides you with a variety of drug discovery and development products based on the Enzyme Fragment Complementation platform for multiple applications to meet your specific IO research needs.
Access Products by Target Families
The development of antibody-based therapeutics to target the killing of tumor cells has revolutionized the space of immuno-oncology and the…
Read MoreWith the increasing industry focus on antibody drugs, there is an ever-greater need for functional bioassays that interrogate the therapeutic…
Read MoreAn Application Note on automating Eurofins DiscoverX Cell-Based PathHunter® PD-1 Signaling Bioassay to bring high-throughput efficiencies to assay workflows. The…
Read MoreAudrey B. Bergeron, B.A. and Hannah J. Gitschier, M.S. Corning Incorporated, Life Sciences Kennebunk, Maine
Read MoreListen to the US PEGS 2023 conference talk by Venkatesh Chari, Ph.D. on MOA-reflective, functional cell-based assays (cell lines and…
Watch NowLearn about the first commercially available SIRPα/CD47 cell-based assay — PathHunter SIRPα Signaling Assay. Find out more about the generation…
Watch NowLearn about PathHunter® checkpoint receptor assays (cell lines and bioassays) for innate and adaptive immunity. Assays discussed include functional cell-based…
Watch NowLearn how KILR® cytotoxicity assays provide a simple, non-radioactive and dye free method to specifically measure target cell death in…
Watch NowLearn how KILR CD16 effector cells ensure assay reproducibility with higher signal-to-background ratios, without worrying about donor variability. PBMC effector…
Watch NowLearn about Eurofins DiscoverX cell line engineering, assay development, and recombinant enzyme production custom capabilities. Find out more about cell…
Watch NowJane E. Lamerdin, Ph.D. Vice President, Research & Development Eurofins DiscoverX
Read MoreGaurav Agrawal, Ph.D.Scientific Development Manager Discover how cell-based assays and translational services accelerate cytokine-based immunotherapeutic development from early discovery to…
Read MoreGaurav Agrawal, Ph.D.Scientific Development Manager
Read MorePresented by Dr. Alexander Baumann Head of European Business Development Eurofins DiscoverXProducts
Read MorePresenter: Jane Lamerdin, Ph.D., Director of R&D, Eurofins DiscoverX
Read MoreDiscoverX CASSS 2017 Presentation Presented by Dr. Jane Lamerdin, Director R&D, DiscoverX May 9, 2017
Read MoreWatch Recorded Presentation Jane Lamerdin, Ph.D. Director R&D, Eurofins DiscoverX
Read MoreGaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX
Read MoreAndrew Green Sr. Business Development Manager
Read MoreJennifer Lin-Jones, Ph.D. Senior Group Leader, Assay Development
Read MoreAndrew Green Senior Business Development Manager
Read MoreDiscoverX PEGS 2017 Presentation Presented By: Jane Lamerdin, Ph.D.
Read MoreGaurav Agrawal, Ph.D. Scientific Development Manager Abstract Millions of deaths worldwide have been attributed to COVID-19, caused by the SARS-CoV-2…
Read MoreGaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX
Read MoreVenkatesh Chari, Ph.D. Scientific Market Development Manager Eurofins DiscoverX Products LLC
Read MoreThe webinar focusses on measuring antibody-mediated cell death using DiscoverX’s KILR Bioassays, and how they can be used to measure…
Watch NowThe webinar focuses on utilizing an InCELL Pulse to characterize small-molecule cellular target engagement. As an example, a case study…
Watch NowCOVID-19 has been declared a global pandemic by WHO. The disease is transmitted when the SARS-CoV-2 virus infects the respiratory…
Watch NowRegulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, which is often exploited…
Watch NowPBMC effector cells have inherent donor variability, reducing their consistency and reproducibility in lot release assays. Antibody-Dependent Cell Cytotoxicity (ADCC)…
Watch NowThe complex interactions between tumor cells and the host immune system are only beginning to be understood, however it is…
Watch NowInherent donor variability of immune effector cells presents a significant challenge for developing a robust and reproducible ADCC assays for…
Watch NowWatch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed…
Watch NowImmune checkpoint receptors play a key role in maintaining antitumor immunity, avert immunopathology, and modulate overall immune homeostasis. However, cancer…
Read MoreReady-to-Use qualified PathHunter® checkpoint bioassays are fit-forpurpose for potency testing for implementation in downstream development phases and Lot release of…
Read MoreTherapeutic regulators require assay data on the impact of Fc effector-mediated function of antibodies during their development as therapeutics. The…
Read MoreRegulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many…
Read MoreRegulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many…
Read MoreReporter genes are a well-established method used to develop cell-based assays for testing drugs that inhibit targets involved in specific…
Read MoreRegulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many…
Read MoreReporter genes are a well-established method used to develop cell-based assays for testing drugs that inhibit or activate targets involved…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional readout for Interleukin receptors.…
Read MoreLigand-induced receptor dimerization is the first functional step in receptor activation, representing the most proximal, functional read-out for receptor activation.…
Read MoreLigand-induced receptor dimerization is the first functional step in receptor activation, representing the most proximal, functional read-out for receptor activation.…
Read MoreLigand-induced receptor dimerization is the first functional step in receptor activation, representing the most proximal, functional read-out for receptor activation.…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…
Read MoreInterleukins are known for their involvement in functioning of both the adaptive and innate immune systems. Interleukins direct immune cells…
Read MoreAntibody-dependent cell-mediated cytotoxicity (ADCC) is the mechanism by which many Class I therapeutic antibodies, including rituximab and trastuzumab, achieve clinical…
Read MoreChimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown…
Read MoreSuccess of ADCC assays is highly dependent on the quality of effector cells used. However, human primary cells (such as…
Read MoreCell-based assays play an important role in determination of mechanism of action (MOA) for therapeutic antibodies, particularly when evaluating their…
Read MoreThe clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory…
Read MoreClass I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen, but also through Fc…
Read MoreFollowing the recent regulatory approvals of a number of checkpoint inhibitor therapeutics, development of a wide array of immunomodulatory therapeutic…
Read MoreThe clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory…
Read MoreCytokines and their receptors have emerged as major drug targets for inflammatory and autoimmune diseases, allergies, and, more recently, in…
Read MoreTherapeutic antibodies that can elicit different applications of cell-mediated cytotoxicity, such as Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and many other effector…
Read MoreThe COVID-19 pandemic has left us racing against time for remediation. As a result, we have witnessed hundreds of therapeutic…
Read MoreClass I therapeutic antibodies achieve their clinical efficacy by binding to their target antigen and through Fragment crystallisable region (Fc)…
Read MoreMost therapeutic antibodies have a Fab’ region that binds the antigen, and an Fc region which binds to and activates…
Read MoreClass I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen but also through Fc…
Read MoreRobust & Reproducible Cell-Based Assays for Potency Testing
Read MoreFunctional Cell-Based Assays, Cell Lines, & Proteins for Cancer Research Improved or novel small molecule or biologic therapeutics for cancer…
Read MoreRobust, Ready-to-Use ADCC & ADCP Bioassays to Accelerate Your Drug Development Program The KILR® cytotoxicity assay platform developed by Eurofins…
Read MoreRobust Cell-Based Assays to Identify Therapeutic Hits Rapidly
Read MoreProducts & Custom Development Capabilities.
Read MoreComprehensive Eurofins DiscoverX product list to enable your drug discovery and development programs focused on checkpoint receptors, cytokine receptors/interleukins, cytotoxicity,…
Read MoreAccelerate your biologics development from discovery to QC lot release with cell-based assays. Comprehensive list of bioassay kits, cell lines,…
Read More
Simple, non-radioactive, & dye-free cytotoxicity assays to specifically measure target cell death
Read More
Comprehensive portfolio of cell-based, functional assays for cytokines & interleukin receptors
Read More
Accelerate cancer immunotherapy drug development with easy-to-use, functional cell-based assays
Read More
Simple, orthogonal reporter-based assays for screening & understanding therapeutic MOAs
Read More
Complete set of parental cell lines, vectors, kits, & retroparticles to build your own stable cell lines & cell-based assays
Read More
Custom cell lines, kits, assays, & protein development capabilities optimized to fit your requirements
Read More